Krsnaa Diagnostics subscribed 1.98 times

Published on Aug 04, 2021 18:00

The initial public offer of Krsnaa Diagnostics received bids for 1.40 crore shares as against 71.12 lakh shares on offer on Wednesday (4 August 2021), according to stock exchange data at 17:00 IST. The issue was subscribed 1.98 times.

The issue opened for bidding on Wednesday (4 August 2021) and it will close on Friday (6 August 2021). The price band of the IPO is fixed at Rs 933-954 per share. An investor can bid for a minimum of 15 equity shares and in multiples thereof.

The IPO comprises of fresh issue of equity shares aggregating up to Rs 400 crore and an offer for sale (OFS) of up to 85,25,520 equity shares by existing shareholders Phi Capita, Kitara, Somerset and Lotus Management Solutions.

Out of the net proceeds from the fresh issue, Rs 150.8 crore will be used to finance the cost of establishing diagnostics centres in Punjab, Karnataka, Himachal Pradesh and Maharashtra; Rs 146.08 crore will be used for repayment/pre-payment of certain borrowings availed by the company; and remaining proceeds will be used for general corporate purposes.

Ahead of the IPO, Krsnaa Diagnostics on 3 August 2021 finalized allocation of 56,28,937 equity shares to anchor investors, at Rs 954 per equity share, aggregating to Rs 537 crore.

Krsnaa Diagnostics offers a range of technology-enabled diagnostic services such as imaging (including radiology), pathology/clinical laboratory and tele-radiology services to public and private hospitals, medical colleges, and community health centres pan-India.

The company also offers a range of diagnostics imaging services and clinical laboratory tests that include both routine and specialized tests / studies and profiles, which are used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases.

The company has an extensive network of integrated diagnostic centres across India primarily in non-metro and lower tier cities and towns. As of June 30, 2021, company operated 1,823 diagnostic centres offering radiology and pathology services in 13 states across India.

The company reported a net profit of Rs 184.92 crore and sales of Rs 396.46 crore in the twelve months ended on 31 March 2021.